FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to thienopyridazine compounds of formula (I) 
and to pharmaceutically acceptable salts and hydrates thereof, wherein R1 and R2 independently mean H or C1-4 alkyl; R3 means a saturated or unsaturated 5- or 6-members ring containing N, S or O, or optical isomers thereof, R4 means phenyl, monosubstituted or disubstituted halogen. The invention also refers to a method for preparing the above compounds and to a pharmaceutical composition for treating and preventing tumour diseases containing the above compounds.
EFFECT: there are prepared new compounds that may be used in medicine for treating anti-tumour diseases, particularly cancer.
12 cl, 3 tbl, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BICYCLIC PYRIDINES AND ANALOGUES AS SIRTUIN MODULATORS | 2010 |
|
RU2550821C2 |
| FXIa INHIBITORS, A METHOD OF THEIR PRODUCTION AND USE IN PHARMACEUTICALS | 2020 |
|
RU2802878C1 |
| HETEROCYCLIC COMPOUNDS AND USES THEREOF | 2014 |
|
RU2680100C9 |
| TRICYCLIC CONDENSED DERIVATIVES OF PYRIDIN-2-ONE AND USE THEREOF AS BRD4 INHIBITORS | 2016 |
|
RU2734959C2 |
| D-AMINO ACID OXIDASE INHIBITORS AND THEIR THERAPEUTIC USE | 2018 |
|
RU2795513C2 |
| PYRROLIDINE DERIVATIVES | 2016 |
|
RU2740019C1 |
| METHOD OF MYOCARDIAL BLOOD PERFUSION IMAGING | 2012 |
|
RU2648358C2 |
| N-HYDROXYFORMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | 2004 |
|
RU2351595C2 |
| COMBINATIVE MEDICINAL AGENT | 2003 |
|
RU2328280C2 |
| 2-OXA-5-AZABICYCLO[2.2.1]HEPTANE-3-YL DERIVATIVES | 2015 |
|
RU2697651C2 |
